Entera Bio Ltd. ENTX 深 滬
已收盤 04-02 16:00:00 美东时间
1.26
+0.120
+10.53%
華盛通- 最 高1.39
- 今 開1.19
- 成交量 74.25万股
- 最 低 1.17
- 昨 收 1.14
- 總市值 5874.40万
- 52周最高 3.22
- 市盈率 靜 --
- 換手率 1.59%
- 52周最低 0.91
- 委 比 -38.24%
- 總股本 4662.22万
- 歷史最高 10.16
- 量 比 4.43
- 振 幅 19.30%
- 歷史最低 0.472
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Entera Bio Announces $10 Million Private Placement Financing
Entera Bio ( ($ENTX) ) has provided an update. On April 1, 2026, Entera Bio ent...
今天 05:04
Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, focus on quarterly earnings of Americas Gold and Silver, ARKO Petroleum, Entera Bio, Phreesia, and Progress Software.
03-30 15:29
Entera Bio Q4 EPS $(0.06) Beats $(0.09) Estimate
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is unchanged from the same period last year.
03-28 04:10
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Entera Bio Ltd., a leader in oral peptide development, reported financial and business updates for 2025, highlighting progress in its pipeline, including EB613 for osteoporosis, EB612 for hypoparathyroidism, and EB618 for metabolic syndromes. FDA alignment on BMD as a primary endpoint for EB613 was achieved, with Phase 3 plans advancing. The company also expanded collaborations with OPKO Health and reported cash reserves of $14.9 million, despite...
03-27 20:05
Entera Bio Submits Clinical Amendment To FDA Providing Streamlined Phase 3 Protocol, SAP, And Open-Label Extension Synopsis To IND 505(B)(2) Submission To Evaluate EB613; Entera Expects FDA Feedback Within 60 Days
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 monthsEB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3
03-04 21:37
Entera Bio Submits Streamlined EB613 Phase 3 Protocol Amendment to FDA
Entera Bio Submits Streamlined EB613 Phase 3 Protocol Amendment to FDA Entera Bio Ltd. said it submitted a clinical amendment to the U.S. Food and Drug Administration for its IND 505(b)(2) program, providing a streamlined Phase 3 protocol, statistical analysis plan and open-label extension synopsis
03-04 21:31
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Entera Bio Ltd. has submitted a streamlined Phase 3 clinical trial protocol for EB613, an oral osteoanabolic therapy for osteoporosis, to the FDA. The trial will assess total hip BMD at 12 months, reducing the target enrollment and accelerating development. The Phase 3 will use the Next-Gen single tablet formulation, replacing the previous multi-tablet version. Topline data is expected in the second half of 2028, approximately one year earlier th...
03-04 13:30
What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours
Entera Bio Ltd. shares jumped 15.71% in after-hours trading following a director's purchase of additional shares.
02-19 14:49
BRIEF-Entera Bio Announces Open Market Purchases Of Company Stock By Board Members
BRIEF-Entera Bio Announces Open Market Purchases Of Company Stock By Board Members Feb 11 (Reuters) - Entera Bio Ltd 5DT.F : ENTERA BIO ANNOUNCES OPEN MARKET PURCHASES OF COMPANY STOCK BY BOARD MEMBERS Source text: ID:nGNX18KS8z Further company coverage: 5DT.F (( Reuters.Briefs@thomsonreuters.com ;)
02-11 22:56
Entera Bio Names Geno Germano Independent Board Chairman
An announcement from Entera Bio ( ($ENTX) ) is now available. Entera Bio announ...
02-09 22:21
